- Home
- REX vs SANA Comparison
REX vs SANA Comparison
Compare REX & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | SANA |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REX | SANA |
|---|---|---|
| Price | $40.96 | $3.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $25.00 | $7.50 |
| AVG Volume (30 Days) | 142.0K | ★ 2.1M |
| Earning Date | 03-26-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $642,491,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $17.11 | N/A |
| P/E Ratio | $34.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.02 | $1.27 |
| 52 Week High | $64.95 | $6.55 |
Technical Indicators
Market Signals| Indicator | REX | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 76.80 | 34.85 |
| Support Level | $31.06 | $2.85 |
| Resistance Level | $55.35 | $3.15 |
| Average True Range (ATR) | 1.31 | 0.23 |
| MACD | 0.40 | -0.03 |
| Stochastic Oscillator | 88.65 | 9.13 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.